Japanese Dainippon's Phase III Schizophrenia Trial Shows Lurasidone Advantage Over Placebo, But Not Against Zyprexa
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitoma Pharma Co. does have enough positive pivotal trials for its planned 2010 NDA filing for the atypical antipsychotic lurasidone, but the newly released data from one of those trials reveal a discrepancy in the efficacy results that could be a hurdle at U.S. FDA
You may also be interested in...
Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble
WASHINGTON - Dainippon Sumitomo submitted an NDA to U.S. FDA for its atypical antipsychotic lurasidone for schizophrenia, and the company is hoping its newly acquired Sepracor sales force is up to the challenge in a crowded, but still fruitful, market
Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble
WASHINGTON - Dainippon Sumitomo submitted an NDA to U.S. FDA for its atypical antipsychotic lurasidone for schizophrenia, and the company is hoping its newly acquired Sepracor sales force is up to the challenge in a crowded, but still fruitful, market
Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble
Company will use newly acquired Sepracor sales force for the atypical antipsychotic.